Search

Descubra cómo MSK utiliza el enfoque de observación y espera para el cáncer de recto, que permite preservar la calidad de vida de los pacientes al tratar con éxito el cáncer de recto sin necesidad de extirpar el recto.

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation, or chemotherapy.

Obtenga información sobre un ensayo clínico en el que se utilizó únicamente inmunoterapia para tratar a personas con varios tipos diferentes de cáncer, lo que significa que no tuvieron que someterse a cirugía, radioterapia ni quimioterapia.

Using genetic engineering, Memorial Sloan Kettering Cancer Center (MSK) physician-scientist Christopher Klebanoff, MD, has led a team of researchers to create a “cloak” that protects cancer-fighting T white blood cells, such as chimeric antigen receptor T cells, from self-destructing. During cancer immunotherapy, immune cells often undergo a form of cellular suicide, termed apoptosis, which can limit the therapy’s effectiveness. The use of “genetic cloaking” prevents immune cell apoptosis, enhancing the effectiveness of cellular immunotherapies for liquid and solid cancers in mouse models. This new technique is also effective in protecting human cancer-fighting immune cells. These findings lay the groundwork for a potentially universal gene-engineering strategy to safely increase the potency of cellular immunotherapies for a broad range of cancers.

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

An MSK program helps lung cancer survivors stay healthy following successful treatment for their disease.

Un programa de MSK ayuda a los sobrevivientes de cáncer pulmonar a mantenerse saludables después de un tratamiento exitoso contra su enfermedad.

Learn how a blood test could someday provide a way to detect cancers at an early stage.